Aragen (Photo: Twitter)
Davos: Cementing Hyderabad’s position as the epicentre for drug discovery and development services in Asia, Aragen Life Sciences announced plans to expand its operations with a new investment of `2,000 crore and create 1,500 new jobs. The investment would help the firm further its existing facility in Mallapur of Telangana state.
The expansion is primarily targeted towards drug discovery, development and manufacturing activities for the global life sciences industry.
The announcement was made after Chief Minister A. Revanth Reddy held a meeting with Manni Kantipudi, full-time director and CEO, Aragen Life Sciences.
The expansion of Aragen Life Sciences has further solidified Hyderabad's status as a hub of contract research organisations in India. Hyderabad serves more than 1,000 innovators globally in their efforts to discover and develop new drugs and devices.
Aragen boasts of more than 20 years of experience, providing a range of contract research, development and manufacturing services across the drug development continuum, with a focus on early-stage discovery and development of new molecular entities (NMEs).
Whether large pharma or biotech, an agrochemical or animal health company, Aragen provides global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules.
Speaking after the meeting, Revanth Reddy said he was delighted that Aragen Life Sciences, a global leader in pharma, chose to intensify its investment plans in Hyderabad. “This shows the new government’s resolve to building a next-level vibrant ecosystem, extraordinary infrastructure and showcasing our rich talent pool that can drive innovation to the works,” he said.
Manni Kantipudi said that they have decided to invest `2,000 crore in Hyderabad. “Chief Minister Revanth Reddy's leadership inspires confidence Hyderabad will consolidate its undisputed national status as headquarters for CROs and CDMOs over the years,” he said.
The announcement was made after Chief Minister A. Revanth Reddy held a meeting with Manni Kantipudi, full-time director and CEO, Aragen Life Sciences.
The expansion of Aragen Life Sciences has further solidified Hyderabad's status as a hub of contract research organisations in India. Hyderabad serves more than 1,000 innovators globally in their efforts to discover and develop new drugs and devices.
Aragen boasts of more than 20 years of experience, providing a range of contract research, development and manufacturing services across the drug development continuum, with a focus on early-stage discovery and development of new molecular entities (NMEs).
Whether large pharma or biotech, an agrochemical or animal health company, Aragen provides global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules.
Speaking after the meeting, Revanth Reddy said he was delighted that Aragen Life Sciences, a global leader in pharma, chose to intensify its investment plans in Hyderabad. “This shows the new government’s resolve to building a next-level vibrant ecosystem, extraordinary infrastructure and showcasing our rich talent pool that can drive innovation to the works,” he said.
Manni Kantipudi said that they have decided to invest `2,000 crore in Hyderabad. “Chief Minister Revanth Reddy's leadership inspires confidence Hyderabad will consolidate its undisputed national status as headquarters for CROs and CDMOs over the years,” he said.
( Source : Deccan Chronicle )
Next Story
